benign prostatic hyperplasia
Urology · 2008–2010
Every decision here pre-dates the consumer comments facility, so no input would be recorded either way.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| dutasteride with tamsulosin hydrochloride Treatment of moderate to severe lower urinary tract symptoms due to benign prostatic hyperplasia (BPH) where treatment has been initiated by a urologist. | Nov 2010 | Recommended with restriction | no section in document |
| tamsulosin hydrochloride Treatment of lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). | Nov 2010 | Recommended with restriction | unclear |
| dutasteride Treatment of benign prostatic hyperplasia (BPH) in men aged 50 years and over with an International Prostate Symptom Score (IPSS) > 7 and a prostate specific… | Jul 2009 | Not recommended | no section in document |
| dutasteride Treatment, in combination with an alpha-antagonist, of lower urinary tract symptoms due to benign prostatic hyperplasia (BPH) where treatment is initiated by a… | Nov 2009 | Recommended with restriction | no section in document |
| tamsulosin hydrochloride Treatment of lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). | Mar 2008 | Not recommended | no section in document |
| tamsulosin hydrochloride Lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). | Nov 2008 | Recommended | no section in document |
What the PBS pays
$177M in government benefit over 2024–25, across 6,347,082 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| dutasteride with tamsulosin hydrochloride | $60.4M |
| dutasteride | $58.9M |
| tamsulosin hydrochloride | $57.2M |
Appraised elsewhere
NICE, in England and Wales, has appraised 1 technology for this condition, recommending 0 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| tadalafilTadalafil for the treatment of symptoms associated with benign prostatic hyperplasia (terminated appraisal) | TA273 | terminated | 2013-01 |
Registered, not subsidised
Medicines on the ARTG for this condition with no PBAC record at all. Registration and subsidy are separate decisions: a medicine can be legally available in Australia and never have been put to the committee.
| Medicine | On the ARTG since | Registrations |
|---|---|---|
| finasterideA&M - FINTAB 1 finasteride 1 mg film-coated tablets blister pack | 1993 | 22 |
| silodosinUROREC silodosin 4 mg hard capsule blister pack | 2017 | 2 |
| alfuzosinXATRAL SR alfuzosin 10mg (as hydrochloride) tablet blister pack | 2002 | 1 |
The ARTG export holds current registrations only, so the year is the earliest entry still on the register rather than a first-registration date. The condition here comes from the registered label, which is usually broader than the population a sponsor asks to have subsidised.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 0 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.